The Cigna Group Earnings - Q2 2026 Analysis & Highlights
The Cigna Group reported strong second quarter 2026 results driven by outperformance in both Evernorth and Cigna Healthcare segments, with management emphasizing operational execution, specialty pharmacy growth, and the transition to a new rebate-free pharmacy benefits model while maintaining full-year earnings guidance.
Key Financial Results
Total revenues of $71.7 billion in the second quarter 2026.
Adjusted earnings per share of $7.78 for the second quarter.
Adjusted after-tax earnings of $2.1 billion during the second quarter.
After-tax special item charges of $153 million or $0.58 per share recorded in the second quarter.
Full-year 2026 adjusted earnings per share outlook raised to at least $30.45.
Business Segment Results
Evernorth revenues grew 6% year-over-year to $61.5 billion in the second quarter with pretax adjusted earnings of $1.7 billion.
Specialty and Care Services delivered pretax adjusted earnings growth of 22% year-over-year to $1.1 billion, ahead of expectations, driven by specialty utilization growth and increased biosimilar adoption.
Specialty generic penetration exceeded 80% for newer products during the quarter.
Pharmacy Benefit Services pretax adjusted earnings were $609 million, down from the prior year due to large client contract renewals and investments in the Signature rebate-free model transition.
Cigna Healthcare revenues grew 10% year-over-year to $11.8 billion with pretax adjusted earnings of $1.3 billion.
Cigna Healthcare medical care ratio was 84.5% for the second quarter, slightly ahead of expectations.
Cigna Healthcare delivered pretax adjusted earnings growth of 17%, driven by strong US Employer business performance.
Capital Allocation
Operating cash flow of approximately $9 billion expected for the full year, mostly back half weighted.
Full-year outlook includes potential impact of future share repurchases and anticipated 2026 dividends.
Modest capital release expected from the ACA Exchange exit, but nothing of significance.
Industry Trends and Dynamics
Specialty pharmacy market approaching $500 billion total addressable market with high-single-digit secular growth moving forward.
Approximately 60% of the specialty pharmacy market is direct-to-patient business where Cigna has achieved industry leadership, with the remaining 40% being provider-administered drugs.
Elevated focus on affordability as new expensive therapies continue to enter the market and demand for complex care grows.
Growing expectations for more personalized healthcare experiences as people want healthcare to feel as easy as other areas of their lives.
Continued economic pressures, geopolitical uncertainty and rapid pace of change fueled by AI advances characterize the current healthcare environment.
Overall cost trends remain elevated but stable in the healthcare market.
Medical cost trends were slightly favorable to expectations during the quarter, reflecting lower outpatient trends including lower surgical spend.
Competitive Landscape
Cigna continues to win in the employer-sponsored healthcare market through deep focus and differentiated expertise generating continued customer growth in the US Employer business.
Disciplined pricing and execution in the stop-loss business where the company continues to make progress on margin recapture.
Ability to continuously innovate by leveraging data and clinical programs that keep people healthy distinguishes Cigna from competitors.
Integrated solutions providing improved access and coordination across medical, pharmacy and behavioral health services represent a competitive advantage.
Provider matching capabilities for behavioral health patients are reducing costs by matching patients with high quality providers.
Shields Health Solutions is the clear leader in the management services space, serving over 80 sizable health systems representing more than 1,000 hospitals across 50 states.
US Employer business customers up 5% year-over-year in the under 500 select segment.
Macroeconomic Environment
Current environment is dynamic with elevated focus on affordability as new expensive therapies continue to enter the market.
Geopolitical uncertainty and rapid pace of change fueled by AI advances characterize the current operating environment.
Employers continue to face trade-off decisions related to the comprehensiveness of employee benefit programs versus the competitiveness of products and solutions in the market.
Growth Opportunities and Strategies
Signature rebate-free pharmacy benefits model showing significant early interest from health plans and employers with broader market launch planned for 2028.
Signature introduction to Cigna Healthcare's fully insured plans planned for next year as an important next step before broader market launch.
2027 representing one of the strongest selling seasons in recent years for Pharmacy Benefit Services.
Expansion of specialty pharmacy services supporting hospitals and health systems through differentiated strengths in Accredo and expanded suite of specialty pharmacy services.
Market-leading access to more than 330 limited distribution medicines positioning Cigna uniquely to serve patients with complex, clinically intensive needs.
Continued investment in US Employer business with more headroom for growth, particularly in the under 500 select segment.
Scaling of international health business, which while a small part of the overall company, has been a very strong source of performance over a multi-year period.
Opportunities to attach additional products such as supplemental health benefits or voluntary benefits as employers look for affordability improvement opportunities.
Three categories of future growth opportunities in health system services: natural secular growth of the market, expansion of percentage of health systems hiring management companies, and mutual value creation opportunities between Shields and Evernorth.
Leveraging data, AI and technology to deliver more personalized healthcare experiences for customers and patients.
Financial Guidance and Outlook
Full-year 2026 adjusted earnings per share outlook of at least $30.45, representing an increase from prior guidance.
Outlook reflects strong first-half performance while maintaining a prudent view of the current environment.
Specialty generics and biosimilars expected to be a meaningful tailwind for the back half of the year.
Magnitude of biosimilar and specialty generic benefit seen in second quarter not expected to repeat at the same level in the third and fourth quarters.
Moderation of GLP-1 growth rates expected to continue through the balance of the year.
Enterprise-level view for 2027 continues to be consistent with 10% to 14% EPS algorithm.
Detailed guidance for 2027 segments to be provided during fourth quarter call.
Transition expenses for Signature model expected to continue at similar levels in 2027, with investment levels ramping down over time.
Investor Day planned for September to discuss advancements in growth strategy and each business.
Pharmacy Benefits Model Transition
Signature model transition tracking exactly to expected spending levels for 2026.
Impact of moving to Signature model varies by client, with those in high deductible plans seeing the most change and those in copay plans seeing minimal impact.
Risk book of business experiencing smooth transition with pricing including all components and client-by-client consultation on plan design changes.
Broader scaling of Signature model planned for 2028 with increased self-funded business.
GLP-1 Coverage and Dynamics
Cigna ended employee coverage of GLP-1 for Wegovy and Zepbound on July 1, citing rising availability and new options.
GLP-1 program continues to be very effective for employers who cover it for weight management, but expected to continue as an area of debate and tension for employers in terms of funding.
Moderating GLP-1 growth observed in second quarter as coverage levels slightly declined and utilization growth moderated from elevated levels in prior periods.
ACA Exchange Exit
Individual exchange exit occurring at the end of calendar year 2026.
Margins in the exchange business expected to be positive but below target levels for 2026, tracking consistently with expectations.
Some stranded overhead expected as the company exits the exchange business, with further details to be provided as the year closes.
No compelling need to enter different end markets following the exchange exit, with continued focus on US Employer business.
